6H-thieno[2,3-b]pyrrole 、 三氟乙酸酐 以
四氢呋喃 为溶剂,
反应 18.0h,
以to give 2,2,2-trifluoro-1-(6H-thieno[2,3-b]pyrrol-4-yl)-ethanone as a beige solid的产率得到2,2,2-trifluoro-1-(6H-thieno[2,3-b]pyrrol-4-yl)-ethanone
参考文献:
名称:
HETEROCYCLIC COMPOUNDS AND THEIR USE AS PESTICIDES
[EN] 6H-THIENO`2, 3-B!PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH)<br/>[FR] DERIVES DE 6H-THIENO`2,3-B!PYRROLE EN TANT QU'ANTAGONISTES DE LA GONADOLIBERINE (GNRH)
申请人:ASTRAZENECA AB
公开号:WO2004018480A1
公开(公告)日:2004-03-04
The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
[EN] SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS DE DCN1 À PETITES MOLÉCULES ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
申请人:UNIV MICHIGAN REGENTS
公开号:WO2018183411A1
公开(公告)日:2018-10-04
Compounds of formula (I) as inhibitors of DCNl and compositions containing the same are disclosed. Methods of using the DCNl inhibitors in the treatment of diseases and conditions wherein inhibition of DCNl provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.
SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS
申请人:Su Wei-Guo
公开号:US20140121200A1
公开(公告)日:2014-05-01
Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R
1
, R
2
, R
3
, R
4
and m are as defined in the specification.
Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same
申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
公开号:US20180289677A1
公开(公告)日:2018-10-11
Small molecule covalent inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.
HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF
申请人:SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
公开号:US20170158680A1
公开(公告)日:2017-06-08
The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.